Bayer Teams Up With Versant to Develop Stem-Cell Therapies

Bayer and U.S. healthcare investor Versant Ventures plan to establish a stem-cell research company called BlueRock Therapeutics, with initial joint funding of $225 million.
Source: WSJ.com: Health - Category: Pharmaceuticals Tags: FREE Source Type: news